PMID- 7130394
OWN - NLM
STAT- MEDLINE
DCOM- 19821216
LR  - 20190606
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 70
IP  - 5
DP  - 1982 Nov
TI  - Hydration of sickle cells using the sodium ionophore Monensin. A model for 
      therapy.
PG  - 1074-80
AB  - Mean cell hemoglobin concentration (MCHC) is thought to have an important 
      influence in sickle cell disease, both through the strong dependence of sickling 
      rates on hemoglobin S concentration, and through the profoundly limiting effect 
      of high MCHC on the rheologic competence of oxygenated, irreversibly sickled 
      cells (ISC). Recent studies have tested the ability of antidiuretic hormone to 
      reduce sickle cell MCHC by reducing plasma sodium (Na) and osmolality. An 
      alternative means of reducing MCHC is to elevate intracellular cation content, 
      rather than to depress extracellular cation concentration. In an effort to do 
      this, we have treated sickle cells with Monensin, an antibiotic that selectively 
      enhances membrane Na permeability. At submicromolar concentrations, Monensin 
      substantially reduced the MCHC of whole sickle blood and isolated ISC, causing an 
      improvement in cell deformability. Monensin's effectiveness in producing a 
      controlled increase in erythrocyte water content suggests that agents that 
      selectively increase membrane Na permeability could be therapeutically useful.
FAU - Clark, M R
AU  - Clark MR
FAU - Mohandas, N
AU  - Mohandas N
FAU - Shohet, S B
AU  - Shohet SB
LA  - eng
GR  - AM 16095/AM/NIADDK NIH HHS/United States
GR  - AM 26263/AM/NIADDK NIH HHS/United States
GR  - HL 20985/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Furans)
RN  - 0 (Hemoglobin, Sickle)
RN  - 0 (Ionophores)
RN  - 9008-00-8 (Hemoglobin C)
RN  - 906O0YJ6ZP (Monensin)
RN  - 9NEZ333N27 (Sodium)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Anemia, Sickle Cell/blood/drug therapy/genetics
MH  - Centrifugation, Density Gradient
MH  - Erythrocytes, Abnormal/*drug effects/metabolism/physiology
MH  - Furans/*pharmacology
MH  - Hemoglobin C/genetics
MH  - Hemoglobin, Sickle/genetics
MH  - Hemolysis/drug effects
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Ionophores/pharmacology/therapeutic use
MH  - Models, Biological
MH  - Monensin/*pharmacology/therapeutic use
MH  - Osmolar Concentration
MH  - Potassium/blood
MH  - Sodium/*blood
MH  - Stimulation, Chemical
MH  - Water-Electrolyte Balance/*drug effects
PMC - PMC370320
EDAT- 1982/11/01 00:00
MHDA- 1982/11/01 00:01
PMCR- 1982/11/01
CRDT- 1982/11/01 00:00
PHST- 1982/11/01 00:00 [pubmed]
PHST- 1982/11/01 00:01 [medline]
PHST- 1982/11/01 00:00 [entrez]
PHST- 1982/11/01 00:00 [pmc-release]
AID - 10.1172/jci110695 [doi]
PST - ppublish
SO  - J Clin Invest. 1982 Nov;70(5):1074-80. doi: 10.1172/jci110695.